WO2013108771A1 - Procédé d'extraction de lysyl oxydase à partir de la membrane de coquille d'œuf - Google Patents

Procédé d'extraction de lysyl oxydase à partir de la membrane de coquille d'œuf Download PDF

Info

Publication number
WO2013108771A1
WO2013108771A1 PCT/JP2013/050628 JP2013050628W WO2013108771A1 WO 2013108771 A1 WO2013108771 A1 WO 2013108771A1 JP 2013050628 W JP2013050628 W JP 2013050628W WO 2013108771 A1 WO2013108771 A1 WO 2013108771A1
Authority
WO
WIPO (PCT)
Prior art keywords
eggshell membrane
eggshell
lysyl oxidase
enzyme
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2013/050628
Other languages
English (en)
Japanese (ja)
Inventor
貴史 小山
俊一 田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amano Enzyme Inc
Original Assignee
Amano Enzyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amano Enzyme Inc filed Critical Amano Enzyme Inc
Publication of WO2013108771A1 publication Critical patent/WO2013108771A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03013—Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/982—Reproductive organs; Embryos, Eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)

Definitions

  • the present invention relates to a method for extracting eggshell membrane useful components. Specifically, the present invention relates to a method for extracting soluble lysyl oxidase from eggshell membranes, use of the extracted soluble lysyl oxidase, and the like.
  • the soluble lysyl oxidase obtained by the extraction method of the present invention is useful in the fields of improving physical properties of food, regenerative medicine, and the like.
  • the eggshell membrane wraps egg cells (egg yolk) and egg white in chicken eggs, and physically isolates them from the outside with the eggshell, protecting the eggs from harmful UV rays, oxygen and drying. It also plays an important role in protecting against infection by foreign organisms such as pathogenic bacteria and viruses.
  • the eggshell membrane also contains antibacterial substances and antibacterial enzymes such as lysozyme and ⁇ -N-acetylglucosaminidase. Furthermore, eggshell membranes are said to contain other special proteins, and their functionality is attracting attention.
  • Lysyl oxidase (EC 1.4.3.13) is present in the eggshell membrane (Non-patent Document 1). This enzyme generates aldehydes (allysine residues) by oxidizing the ⁇ -amino group of lysine residues in proteins, and is involved in the crosslinking reaction of proteins such as collagen and elastin. Lysyl oxidase is expected to be used and applied in various fields such as substance processing and wound healing. Lysyl oxidase is abundantly contained in the eggshell membrane, but its extraction is extremely difficult due to the strong fiber structure in the eggshell membrane.
  • the present inventors have intensively studied to solve the above problems. Among them, the present inventors paid attention to the eggshell membrane treatment method using an enzyme. There have been reports on solubilization of eggshell membranes using proteolytic enzymes, but no practical technique has been established that can extract soluble useful components in high yield. As a result of the study, the present inventors have found a method for recovering lysyl oxidase in eggshell membranes in high yield using a proteolytic enzyme. Among other proteolytic enzymes, it has also been found that the use of mold-derived proteases and Bacillus-derived proteases is extremely effective for the method. The following present invention was completed mainly based on the above results.
  • a method for extracting soluble lysyl oxidase from an eggshell membrane which comprises causing a microorganism-derived proteolytic enzyme to act on the eggshell membrane.
  • the method according to [1], wherein the microorganism is mold.
  • the mold is Aspergillus.
  • the Aspergillus mold is Aspergillusguards.
  • the method according to [1], wherein the microorganism is a microorganism derived from the genus Bacillus.
  • the microorganism derived from the genus Bacillus is Bacillus subtilis.
  • a pharmaceutical composition comprising the eggshell membrane extract according to [7].
  • Measurement results of lysyl oxidase activity Absorbance at 500 nm was measured for a sample in which eggshell membranes were chemically treated. Measurement results of lysyl oxidase activity. Absorbance at 500 nm was measured for a sample obtained by treating the eggshell membrane with a reducing agent. Measurement results of lysyl oxidase activity. The absorbance at 500 nm was measured for a sample obtained by enzymatically treating eggshell membranes. Measurement results of lysyl oxidase activity. The absorbance at 500 nm was measured for a sample in which the enzyme solution prepared for each enzyme concentration (1%, 0.1%) and each pH was applied to the eggshell membrane.
  • Measurement results of lysyl oxidase activity Absorbance at 500 nm was measured for samples in which the enzyme solution was allowed to act on the eggshell membrane at each reaction temperature (4 ° C., 30 ° C., 40 ° C., 50 ° C., 60 ° C.). Measurement results of lysyl oxidase activity. Absorbance at 500 nm was measured for each reaction time (0 hour, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours) for the sample in which the enzyme solution was allowed to act on the eggshell membrane. The results are shown for each pH.
  • the first aspect of the present invention relates to a method for extracting soluble lysyloxidase from eggshell membrane. According to the method of the present invention, soluble lysyl oxidase from eggshell membranes can be efficiently extracted and recovered. Moreover, a high recovery rate can be achieved without performing pretreatment.
  • the “egg shell membrane” is a membrane that exists inside the outer shell of avian eggs such as chickens, quails, rib chickens, ducks, geese, and ostriches.
  • the state of the eggshell membrane used for the treatment is not particularly limited. For example, after separation from the outer shell, dried (vacuum dried, suction dried, freeze dried, etc.) (dried state), before dried (wet state), swollen after dried (Wet state) can be used. Moreover, the thing (for example, powder form) to which processes, such as cutting and grinding
  • the extraction method of the present invention is characterized by “acting a microorganism-derived proteolytic enzyme on the eggshell membrane”.
  • a step of causing a microorganism-derived proteolytic enzyme to act on the eggshell membrane is performed.
  • the timing (time) at which the proteolytic enzyme acts on the eggshell membrane is not particularly limited.
  • the solvent used in step (1) is not particularly limited as long as an enzyme reaction occurs, but preferably a buffer solution is used to facilitate pH adjustment and maintenance of a desired pH.
  • the proteolytic enzyme used in the present invention is not particularly limited as long as lysyl oxidase can be efficiently extracted from the eggshell membrane.
  • a commercially available enzyme agent may be used as a proteolytic enzyme.
  • enzyme agents include biosoak, neurose F3-G, neurose A, protease N “Amano” G, protease S “Amano” G, promeline F, Samoase PC10F, proleather FG-F, protease P “ Amano 3G, Protease P Amano 3DS (above Amano Enzyme), Morsin F (Kikkoman Foods), Sumiteam AP, Sumiteam LP, Sumiteam LP500, Sumiteam FP, Sumiteam LPL, Sumiteam MP (above, Shin Nippon Chemical Industry), Denapsin 2P, Denateam AP, Bioprelase OP, Bioprelase AL-15FG, Bioprelase 30G, Bioprelase APL-30, Bioprelase
  • an enzyme derived from Aspergillus or Bacillus microorganisms can be used.
  • one or more enzymes selected from the group consisting of Aspergillusbushess and Bacillus subtilis can be used.
  • an enzyme derived from Aspergillusnets can be used.
  • an enzyme agent derived from Aspergillusnets for example, protease P “Amano” 3SD (Amano Enzyme) can be used, and as an enzyme agent derived from Bacillus subtilis, for example, Proleza® FG-F (Amano Enzyme) can be used.
  • the proteolytic enzyme used in the present invention may not be a purified product.
  • Culture extracts from microorganisms or partially purified products thereof can be used as proteolytic enzymes as long as efficient extraction of lysyl oxidase in eggshell membranes can be achieved.
  • the reaction time of step (2) can be arbitrarily set within a range of 1 hour to 24 hours, for example. In order to increase the reaction efficiency, stirring or shaking may be added.
  • the temperature conditions are not particularly limited, and may be set within a range that does not hinder the action of the proteolytic enzyme used.
  • An example of the temperature condition is 30 ° C. to 80 ° C.
  • a preferred temperature condition is 40 ° C to 70 ° C.
  • the amount (addition concentration) of the proteolytic enzyme is not particularly limited as long as efficient extraction of lysyl oxidase from the eggshell membrane is possible.
  • the amount of the enzyme in which the concentration of the proteolytic enzyme in the reaction solution is 0.01% (W / W) to 20% (W / W), although the optimum amount used varies depending on the type of enzyme used. Is used.
  • the concentration of the proteolytic enzyme in the reaction solution is preferably 0.1% (W / W) to 20% (W / W), more preferably 0.1% (W / W) to 10% (W / W) It is.
  • purification is performed after the extraction step. That is, a step of purifying lysyl oxidase derived from eggshell membranes obtained in the extraction step is performed.
  • the eggshell membrane extract is purified by an appropriate combination of filtration, centrifugation, desalting, salting out such as ammonium sulfate precipitation, dialysis, and various chromatography (ion exchange chromatography, hydrophobic chromatography, affinity chromatography, etc.). To do.
  • the eggshell membrane extract obtained by the extraction method of the present invention is subjected to treatments such as drying (spray drying, etc.), freezing, lyophilization, etc. as necessary.
  • Eggshell membrane extract containing soluble lysyl oxidase The second aspect of the present invention provides an eggshell membrane extract containing the soluble lysyl oxidase extracted by the eggshell membrane extraction method of the present invention. According to the eggshell membrane extraction method of the present invention, soluble lysyl oxidase can be extracted under mild conditions. Therefore, it is possible to obtain a highly active soluble lysyl oxidase.
  • proteins including lysozyme, ⁇ -N-acetylglucosaminidase, collagen proteins), glycoproteins, peptides (including collagen peptides) contained in eggshell membranes ), Glycopeptides, amino acids, hyaluronic acid, chondroitin sulfate, acidic mucopolysaccharides such as dermatan sulfate, and the like.
  • the eggshell membrane extract obtained by the extraction method of the present invention contains one or more components selected from the group consisting of lysozyme, ⁇ -N-acetylglucosaminidase, hyaluronic acid, chondroitin sulfate, and dermatan sulfate. .
  • the present invention also provides a composition containing an eggshell membrane extract containing soluble lysyl oxidase.
  • the use of the extract of the present invention is not particularly limited, but is preferably a medicine, quasi drug, food or cosmetic. That is, the present invention provides a pharmaceutical composition, an quasi-drug composition, a food composition, and a cosmetic composition containing an eggshell membrane extract as a preferred embodiment.
  • Examples of uses or effects of the pharmaceutical composition and quasi-drug composition of the present invention include antioxidant, antibacterial, anti-inflammatory, wound treatment, blood pressure reduction, hair growth, and nutritional support.
  • Preparation of the pharmaceutical composition and quasi-drug composition of the present invention can be performed according to a conventional method.
  • other pharmaceutically acceptable ingredients for example, carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, preservatives, physiological Saline solution and the like.
  • excipient lactose, starch, sorbitol, D-mannitol, sucrose and the like can be used.
  • disintegrant starch, carboxymethylcellulose, calcium carbonate and the like can be used. Phosphate, citrate, acetate, etc. can be used as the buffer.
  • emulsifier gum arabic, sodium alginate, tragacanth and the like can be used.
  • suspending agent glyceryl monostearate, aluminum monostearate, methyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, sodium lauryl sulfate and the like can be used.
  • soothing agent benzyl alcohol, chlorobutanol, sorbitol and the like can be used.
  • stabilizer propylene glycol, ascorbic acid or the like can be used.
  • preservatives phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methylparaben, and the like can be used.
  • preservatives benzalkonium chloride, paraoxybenzoic acid, chlorobutanol and the like can be used.
  • the dosage form in the case of formulating is also not particularly limited, and the pharmaceutical composition or pharmaceutical of the present invention can be used as tablets, powders, fine granules, granules, capsules, syrups, injections, external preparations, suppositories, etc.
  • An quasi-drug composition can be provided.
  • the pharmaceutical composition of the present invention contains an active ingredient in an amount necessary for obtaining an expected therapeutic effect or preventive effect (that is, a therapeutically effective amount).
  • the quasi-drug composition of the present invention contains an active ingredient in an amount necessary for obtaining the expected improvement effect, prevention effect and the like.
  • the amount of the active ingredient contained in the pharmaceutical composition or quasi-drug composition of the present invention generally varies depending on the dosage form and form, but the amount of the active ingredient is, for example, about 0.1% by weight to achieve a desired dose. Set within the range of about 95% by weight.
  • the pharmaceutical composition and quasi-drug composition of the present invention are orally or parenterally (intravenous, intraarterial, subcutaneous, intramuscular or intraperitoneal injection, transdermal, nasal, transmucosal depending on the dosage form and form. , Application, etc.).
  • the “subject” here is not particularly limited, and includes humans and non-human mammals (including pet animals, domestic animals, laboratory animals. Specifically, for example, mice, rats, guinea pigs, hamsters, monkeys, cows, pigs, goats. , Sheep, dogs, cats, chickens, quails, etc.).
  • the application subject is a human.
  • the dosage and usage of the pharmaceutical composition and quasi-drug composition of the present invention are set so as to obtain the expected effect.
  • the symptom, age, sex, weight, etc. of the subject of application are generally considered.
  • a person skilled in the art can set an appropriate dose in consideration of these matters.
  • the administration schedule for example, once to several times a day, once every two days, or once every three days can be adopted.
  • the symptom of the application target, the duration of effect of the active ingredient, and the like can be considered.
  • one aspect of the present invention is a food composition containing an eggshell membrane extract obtained by the eggshell membrane extraction method of the present invention.
  • the “food composition” in the present invention include general foods (cereals, vegetables, meat, various processed foods, confectionery, milk, soft drinks, alcoholic beverages, etc.), dietary supplements (antioxidants, antibacterials, anti-inflammatorys) , Supplements and nutritional drinks for the purpose of treating wounds, lowering blood pressure, preventing aging, etc.) and food additives.
  • a dietary supplement or food additive it can be provided in the form of powder, granule powder, tablet, paste, liquid or the like.
  • the amount of eggshell membrane extract added can be arbitrarily set according to the purpose. For example, when the food composition of the present invention is expected to have an effect that contributes to the maintenance or promotion of health or the treatment or prevention of a specific disease or condition, a sufficient amount of eggshell membrane extraction is required to exhibit the effect. It is preferable to contain a product.
  • the amount added can be determined in consideration of the type of food, the consumer of the food (sex, age, weight, etc.), the effect expected of the food.
  • one aspect of the present invention is a cosmetic composition containing an eggshell membrane extract obtained by the eggshell membrane extraction method of the present invention.
  • the cosmetic composition of the present invention comprises an eggshell membrane extract and ingredients / bases commonly used in cosmetics (for example, various fats and oils, mineral oil, petrolatum, squalane, lanolin, beeswax, denatured alcohol, dextrin palmitate, glycerin). Glycerin fatty acid ester, ethylene glycol, paraben, camphor, menthol, various vitamins, zinc oxide, titanium oxide, benzoic acid, edetic acid, chamomile oil, carrageenan, chitin powder, chitosan, fragrance, coloring agent, etc.) Obtainable.
  • the cosmetic composition examples include emulsions for face or body, lotions, creams, lotions, essences, oils, packs, sheets, and cleaning agents.
  • the addition amount of the eggshell membrane extract in the cosmetic composition is not particularly limited.
  • the eggshell membrane extract may be added so as to be 0.1 wt% to 60 wt%.
  • uses or effects of the cosmetic composition of the present invention include moisture retention, infiltration, prevention of rough skin, beautiful skin, prevention of wrinkles, prevention of sagging and prevention of aging.
  • the eggshell membrane extract of the present invention is also expected to be used in metal ion recovery, humectants, water absorbents, antibacterial agents and the like.
  • Lysyl oxidase activity measurement method (plate assay method) Egg shell membrane extract is allowed to act on the substrate n-butylamine. Hydrogen peroxide generated in this reaction is reacted with 4-aminoantipyrine and phenol in the presence of peroxidase. The absorbance of the red quinone dye obtained by this reaction is determined with a spectrophotometer, and the lysyl oxidase activity in the eggshell membrane extract is determined from the absorbance. Add 0.013% by weight of 4-aminoantipyrine and 0.175% by weight of phenol to potassium phosphate buffer (pH 7.0) to obtain a color developing solution.
  • potassium phosphate buffer pH 7.0
  • the LOX elution fraction was desalted with 20 mM potassium phosphate buffer (pH 7.0) by ultrafiltration (10,000 MWCO). This was used as a purified LOX solution, and the LOX activity was measured by the method (9) below.
  • LOX activity measurement method (cell method) The LOX activity of the purified LOX solution obtained in (8) above was measured. Purified LOX solution was allowed to act on the substrate n-butylamine to obtain hydrogen peroxide. This hydrogen peroxide was reacted with 4-aminoantipyrine and phenol in the presence of peroxidase. The absorbance at an absorption wavelength of 500 nm of the red quinone dye obtained by this reaction was determined with a spectrophotometer, and the LOX activity in the eggshell membrane extract was determined from this absorbance. 4-aminoantipyrine 0.013% by weight and phenol 0.175% by weight were added to potassium phosphate buffer (pH 7.0) to obtain a color developing solution.
  • a reaction solution was prepared by adding 10 ⁇ L of 1M n-butylamine and 100 ⁇ L of 70 u / mL peroxidase to 890 ⁇ L of the coloring solution obtained above, and adding purified water to 1 mL. The measurement was performed by adding 3 mL of the reaction solution to 100 ⁇ L of purified LOX solution and reacting at 37 ° C. for 6 minutes, and measuring the increase in absorbance value at an absorption wavelength of 500 nm from 2 minutes to 5 minutes every minute. The activity value was calculated as follows (Equation 1).
  • soluble lysyl oxidase can be recovered from eggshell membranes in high yield.
  • the soluble lysyl oxidase extracted by the extraction method of the present invention is expected to be applicable to various fields such as food and pharmaceutical fields.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2013/050628 2012-01-17 2013-01-16 Procédé d'extraction de lysyl oxydase à partir de la membrane de coquille d'œuf Ceased WO2013108771A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-007499 2012-01-17
JP2012007499 2012-01-17

Publications (1)

Publication Number Publication Date
WO2013108771A1 true WO2013108771A1 (fr) 2013-07-25

Family

ID=48799196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/050628 Ceased WO2013108771A1 (fr) 2012-01-17 2013-01-16 Procédé d'extraction de lysyl oxydase à partir de la membrane de coquille d'œuf

Country Status (2)

Country Link
JP (1) JPWO2013108771A1 (fr)
WO (1) WO2013108771A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008007419A (ja) * 2006-06-27 2008-01-17 Ifuji Sangyo Co Ltd 鶏卵卵殻膜を原料とするタンパク質分解酵素による卵殻膜加水分解物とその製法、並びにこれらを添加した機能物
WO2012029529A1 (fr) * 2010-08-31 2012-03-08 天野エンザイム株式会社 Procédé de solubilisation de membranes de coquilles d'œufs utilisant des enzymes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008007419A (ja) * 2006-06-27 2008-01-17 Ifuji Sangyo Co Ltd 鶏卵卵殻膜を原料とするタンパク質分解酵素による卵殻膜加水分解物とその製法、並びにこれらを添加した機能物
WO2012029529A1 (fr) * 2010-08-31 2012-03-08 天野エンザイム株式会社 Procédé de solubilisation de membranes de coquilles d'œufs utilisant des enzymes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKAGAWA M. ET AL.: "Lysyl oxidase coupled with catalase in eggshell membrane", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1434, 1999, pages 151 - 160, XP004278783 *
MITSUGU AKAGAWA ET AL.: "Matrix to shiteno Rankakumaku ni Fukumareru Lysyl Oxidase ni Tsuite", DAI 46 KAI MATRIX KENKYUKAI TAIKAI, 1999, pages 34 - 35 *
TAKAHASHI K. ET AL.: "Soluble egg shell membrane protein as a regulating material for collagen matrix reconstruction", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 60, no. 8, 1996, pages 1299 - 1302 *
TOMOKO AOKI ET AL.: "Keirankakumakuchu no Lysyl Oxidase no Kayoka to sono Oyo", JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY TOHOKU SHIBU TAIKAI PROGRAM KOEN YOSHISHU, 2007, pages 7 *

Also Published As

Publication number Publication date
JPWO2013108771A1 (ja) 2015-05-11

Similar Documents

Publication Publication Date Title
JP5985394B2 (ja) 酵素を用いた卵殻膜の可溶化方法
JP5588474B2 (ja) コラーゲンおよび／またはヒアルロン酸産生促進用組成物
KR101980361B1 (ko) 콜라겐 트리펩타이드를 고함량으로 함유하는 콜라겐 가수분해물 및 이의 용도
CN102573867A (zh) 用于治疗退行性关节病的组合物
JP5084393B2 (ja) コラーゲン産生促進能及び／又は線維芽細胞増殖促進能を有する組成物
TW201536341A (zh) 紅藜萃取物用於製備促進膠原蛋白生成及抗皮膚老化之組合物之用途
JPWO2005077349A1 (ja) ヒトβディフェンシン産生促進剤
JP4917584B2 (ja) 可溶化蜂の子処理物、その製造方法、抗酸化剤、ａｃｅ阻害剤、血圧降下剤、皮膚繊維芽細胞増殖促進剤、疲労回復剤、血流改善剤、並びに可溶化蜂の子処理物を含有する医薬品、化粧品又は飲食品
Zhang et al. Preparation of the enzymatic hydrolysates from Chlorella vulgaris protein and assessment of their antioxidant potential using Caenorhabditis elegans
CN115400054A (zh) 一种基于桑资源的美白抗氧化组合物的制备方法和应用
JP6807535B2 (ja) 線維芽細胞増殖剤
JP5164904B2 (ja) ハチノコ、ローヤルゼリーまたはそれらの抽出物の低褐変化酵素処理物およびその調製方法
US20160331798A1 (en) Natural product inhibitors of 3dg
WO2025201499A1 (fr) Extrait d'esturgeon riche en peptides antioxydants, son procédé de préparation et son utilisation
JPH10265403A (ja) チロシナーゼ活性阻害剤
JP6486745B2 (ja) 美白用組成物
JP2003245055A (ja) 肌改善用食品組成物及び肌改善方法
JP6660519B1 (ja) エラスターゼ阻害剤
WO2013108771A1 (fr) Procédé d'extraction de lysyl oxydase à partir de la membrane de coquille d'œuf
JP2017132747A (ja) ＡＧＥｓ産生抑制剤
JP6473024B2 (ja) メラニン産生抑制剤
WO2021176707A1 (fr) Composition orale pour inhiber l'élastase et son utilisation, inhibiteur de l'élastase, et procédé d'inhibition de l'activité de l'élastase par ingestion orale d'un inhibiteur de l'élastase
KR102887731B1 (ko) 누에고치 효소 가수분해물을 포함하는 항염증용 조성물
KR20120049042A (ko) 홍합 가수분해물을 유효성분으로 함유하는 항산화제 조성물
JP5717433B2 (ja) 胆汁酸吸着用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13738050

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013554300

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13738050

Country of ref document: EP

Kind code of ref document: A1